Construction of China's first cell drug industrialization base starts in BDA
The foundation of Immunotech Biopharm Cell Drug Industrialization Base is laid. [Photo/kfqgw.beijing.gov.cn]
The Immunotech Biopharm Cell Drug Industrialization Base officially started construction in the Beijing Economic and Technological Development Area on June 17.
As a comprehensive pilot spot for the expansion and opening of Beijing's service industry, and also one of the first one hundred key projects formulated by the BDA this year, the initiation of the project is of milestone significance for the rapid advancement of the industrialization and commercialization of Immunotech Biopharm's cell drugs.
Immunotech Biopharm's blockbuster products include the amplification of activated lymphocytes (abbreviated as: EAL®), which has led to cellular immunotherapy, a breakthrough in the treatment of solid tumors.
As the first cellular immunotherapy product in China to start clinical trials for solid tumors, EAL® is indicated for liver cancer and can be used for treatment after hepatectomy to prevent recurrence.
Beijing Immunotech Biopharm Ltd is China's first innovative biotechnology company engaged in the research and development of cellular immunotherapy products.
The Immunotech Biopharm "Cell Drug Industrialization Base" covers an area of 34,996 square meters. With an investment of 1.2 billion yuan, the base is expected to be under construction for two and a half years, and is expected to be completed and put into operation in 2023.
The project is to include three parts: a cell drug translational medical research center, a cell drug preparation center and a standardization and individualized cellular immunity research and development production complex, which will be used for the industrialization R&D and application of a series of biological cell technologies represented by the amplification of activated lymphocytes (EAL®).
After completion, it is expected to become the first domestic immune cell production and preparation industrial base that meets GMP requirements, and to have an estimated annual output value of about 3.5 billion yuan.
The Immunotech Biopharm Cell Drug Industrialization Base starts construction. [Photo/kfqgw.beijing.gov.cn]
As the main platform for Beijing in building an international science and technology innovation center, the BDA regards the biotechnology and massive health industry as one of its four leading industries. The output value of this industry has been more than 50 percent of that of Beijing as a whole for five consecutive years.